CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents

Abstract

The tumorigenic potential of dulaglutide was evaluated in rats and transgenic mice. Rats were injected sc twice weekly for 93 weeks with dulaglutide 0, 0.05, 0.5, 1.5, or 5 mg/kg corresponding to 0, 0.5, 7, 20, and 58 times, respectively, the maximum recommended human dose based on plasma area under the curve. Transgenic mice were dosed sc twice weekly with dulaglutide 0, 0.3, 1, or 3 mg/kg for 26 weeks. Dulaglutide effects were limited to the thyroid C-cells. In rats, diffuse C-cell hyperplasia and adenomas were statistically increased at 0.5 mg/kg or greater (P ≤ .01 at 5 mg/kg), and C-cell carcinomas were numerically increased at 5 mg/kg. Focal C-cell hyperplasia was higher compared with controls in females given 0.5, 1.5, and 5 mg/kg. In transgenic mice, no dulaglutide-related C-cell hyperplasia or neoplasia was observed at any dose; however, minimal cytoplasmic hypertrophy of C cells was observed in all dulaglutide groups. Systemic exposures decreased over time in mice, possibly due to an antidrug antibody response. In a 52-week study designed to quantitate C-cell mass and plasma calcitonin responses, rats received twice-weekly sc injections of dulaglutide 0 or 5 mg/kg. Dulaglutide increased focal C-cell hyperplasia; however, quantitative increases in C-cell mass did not occur. Consistent with the lack of morphometric changes in C-cell mass, dulaglutide did not affect the incidence of diffuse C-cell hyperplasia or basal or calcium-stimulated plasma calcitonin, suggesting that diffuse increases in C-cell mass did not occur during the initial 52 weeks of the rat carcinogenicity study.

Overview

Integrity signals

Registry

Crossref · 10.1210/en.2014-1722

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 36

Metadata

Authors
Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., Long, G. G., Martin, J. A., & Vahle, J. L.
Affiliations
  • Eli Lilly (United States) (US)
  • Covance (United States) (US)
  • The Ohio State University (US)
  • Experimental Pathology Laboratories (US)
Venue
Endocrinology
Published
2015-04-10
Volume
156
Issue
7
Pages
2417-2428
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2003463625
Cited by
36
References
26
Citations by year
2026: 5 · 2025: 6 · 2024: 3 · 2023: 8 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2017: 2 · 2016: 4 · 2015: 2
FWCI
2.32
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Carcinogens and Genotoxicity Assessment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords
dulaglutide, GLP-1 receptor agonists, thyroid adenoma, carcinogenicity, chronic toxicity, transgenic mice, rats, calcitonin
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Calcitonin, Glucagon-Like Peptides, Female, Hyperplasia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Mice, Transgenic, Organ Size, Recombinant Fusion Proteins, Thyroid Gland, Thyroid Neoplasms, Carcinogenicity Tests, Proto-Oncogene Proteins p21(ras), Receptors, Glucagon, Carcinoma, Neuroendocrine, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents. https://app.cochat.ai/papers/10.1210/en.2014-1722
The paper
Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., Long, G. G., Martin, J. A., & Vahle, J. L. (2015). Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents. Endocrinology. https://doi.org/10.1210/en.2014-1722

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.